BR112023004167A2 - Células-tronco mesenquimais que coexpressam cxcr4 e il-10 e usos das mesmas - Google Patents

Células-tronco mesenquimais que coexpressam cxcr4 e il-10 e usos das mesmas

Info

Publication number
BR112023004167A2
BR112023004167A2 BR112023004167A BR112023004167A BR112023004167A2 BR 112023004167 A2 BR112023004167 A2 BR 112023004167A2 BR 112023004167 A BR112023004167 A BR 112023004167A BR 112023004167 A BR112023004167 A BR 112023004167A BR 112023004167 A2 BR112023004167 A2 BR 112023004167A2
Authority
BR
Brazil
Prior art keywords
cxcr4
stem cells
mesenchymal stem
coexpress
mscs
Prior art date
Application number
BR112023004167A
Other languages
English (en)
Portuguese (pt)
Inventor
Hervás-Salcedo Rosario
García-Olmo Damián
García-Arranz Mariano
Hernando Rodríguez Miriam
Antonio Bueren Roncero Juan
María Yáñez González Rosa
FERNÁNDEZ GARCÍA María
López Santalla Mercedes
Inmaculada Garin Ferreira Marina
Original Assignee
Fundacion Instituto De Investig Sanitaria Fundacion Jimenez Diaz
Centro De Investig Energeticas Medioambientales Y Tecnologicas O A M P
Consorcio Centro De Investig Biomedica En Red
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacion Instituto De Investig Sanitaria Fundacion Jimenez Diaz, Centro De Investig Energeticas Medioambientales Y Tecnologicas O A M P, Consorcio Centro De Investig Biomedica En Red filed Critical Fundacion Instituto De Investig Sanitaria Fundacion Jimenez Diaz
Publication of BR112023004167A2 publication Critical patent/BR112023004167A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/20—Vector systems having a special element relevant for transcription transcription of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BR112023004167A 2020-09-07 2021-09-07 Células-tronco mesenquimais que coexpressam cxcr4 e il-10 e usos das mesmas BR112023004167A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20382792.8A EP3964265A1 (en) 2020-09-07 2020-09-07 Mesenchymal stem cells co-expressing cxcr4 and il-10 and uses thereof
PCT/EP2021/074612 WO2022049306A1 (en) 2020-09-07 2021-09-07 Mesenchymal stem cells co-expressing cxcr4 and il-10 and uses thereof

Publications (1)

Publication Number Publication Date
BR112023004167A2 true BR112023004167A2 (pt) 2023-05-09

Family

ID=72473480

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023004167A BR112023004167A2 (pt) 2020-09-07 2021-09-07 Células-tronco mesenquimais que coexpressam cxcr4 e il-10 e usos das mesmas

Country Status (11)

Country Link
US (1) US20230398152A1 (https=)
EP (2) EP3964265A1 (https=)
JP (1) JP2023540599A (https=)
KR (1) KR20230082622A (https=)
CN (1) CN116507733A (https=)
AU (1) AU2021337798A1 (https=)
BR (1) BR112023004167A2 (https=)
CA (1) CA3194344A1 (https=)
MX (1) MX2023002741A (https=)
SA (1) SA523442866B1 (https=)
WO (1) WO2022049306A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020092839A1 (en) 2018-10-31 2020-05-07 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
EP3873540A4 (en) 2018-10-31 2022-07-27 Mayo Foundation for Medical Education and Research METHODS AND MATERIALS FOR THE TREATMENT OF CANCER
CN115927178A (zh) * 2022-11-17 2023-04-07 华夏源(上海)生物科技有限公司 一种检测间充质干细胞抑制b细胞分化为浆细胞的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2065396A1 (en) * 1996-08-30 2009-06-03 Human Genome Sciences, Inc. Interleukin-19
US20090074733A1 (en) * 2005-12-09 2009-03-19 Medin Jeffrey A Thymidylate kinase mutants and uses thereof
CA2784861A1 (en) * 2009-12-21 2011-07-14 Pharmathene, Inc. Recombinant butyrylcholinesterases and truncates thereof
PL3242933T3 (pl) * 2015-01-08 2019-08-30 Apceth Gmbh & Co. Kg Zmodyfikowane genetycznie mezenchymalne komórki macierzyste wykazujące ekspresję alfa-1 antytrypsyny (aat)
JP7086928B2 (ja) * 2016-07-25 2022-06-20 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 改変されたナチュラルキラー細胞を生成する方法および使用方法
AU2019291069B2 (en) * 2018-06-19 2026-02-19 Fondazione Centro San Raffaele Production of engineered dendritic cells and uses thereof

Also Published As

Publication number Publication date
MX2023002741A (es) 2023-05-26
SA523442866B1 (ar) 2024-05-05
WO2022049306A1 (en) 2022-03-10
CA3194344A1 (en) 2022-03-10
CN116507733A (zh) 2023-07-28
AU2021337798A1 (en) 2023-05-18
US20230398152A1 (en) 2023-12-14
JP2023540599A (ja) 2023-09-25
KR20230082622A (ko) 2023-06-08
EP4210834A1 (en) 2023-07-19
EP3964265A1 (en) 2022-03-09

Similar Documents

Publication Publication Date Title
BR112023004167A2 (pt) Células-tronco mesenquimais que coexpressam cxcr4 e il-10 e usos das mesmas
Lisak et al. B cells from patients with multiple sclerosis induce cell death via apoptosis in neurons in vitro
BR112021022666A2 (pt) Frações de separação e seus métodos e uso
MX2020014296A (es) Variantes de interleucina-2 y sus métodos de uso.
MX2021001837A (es) Constructos del receptor de celulas t y usos de los mismos.
BRPI0921799B8 (pt) compostos que expandem células-tronco hematopoétticas
DOP2017000097A (es) Composiciones y métodos de uso para tratar trastornos metabólicos
BR112015018104A2 (pt) polipeptídeos de gdf15 modificados, seu uso, composições compreendendo os mesmos e recipiente estéril compreendendo as referidas composições
CL2017000201A1 (es) Composiciones y métodos de uso para tratar trastornos metabólicos
CO2020004383A2 (es) Método de obtención de una composición que contiene una población específica de células mesenquimales de cordón umbilical y sus usos
BR112022019060A2 (pt) Células neurais hipoimunogênicas para o tratamento de distúrbios e condições neurológicas
ECSP20082338A (es) Receptores del factor de crecimiento quimérico
CL2021003201A1 (es) Vectores aav con el promotor de la proteína cero de mielina y usos de los mismos para el tratamiento de enfermedades asociadas a las células de schwann como la enfermedad de charcot-marie-tooth.
CU20210041A7 (es) Péptidos inmunogénicos con motivos de oxidorreductasa
MX2021005346A (es) Constructos de suministro para transcitosis y metodos relacionados.
BR112015019729A2 (pt) composição inibidora da il-1b e uso da mesma
MX2024008571A (es) Células beta hipoinmunes diferenciadas de las células madre pluripotentes y usos y métodos relacionados.
Tyndall et al. Stem cell transplantation and mesenchymal cells to treat autoimmune diseases
WO2019113375A3 (en) Dosing regimens for the mobilization of hematopoietic stem and progenitor cells
BR112020004935A8 (pt) Composição farmacêutica compreendendo um anticorpo que se liga especificamente a n-terminal de lisil-trna sintetase como princípio ativo para prevenção ou tratamento de doença relacionada com migração celular
BR112018072045A8 (pt) Proteína de fusão, método de preparação da proteína, ácido nucleico, vetor e célula, composição farmacêutica e variante de ccl3ss
Tomotake MITOCHONDRIAL DYNAMICS AND MITOPHAGY
Lakshmi et al. A noval approach for treating cancer by using laccases from marine fungi
Gao Comparison of the cytotoxic activity of different human γδ T cell subsets against influenza virus infected cells
Zyromski et al. Dear IHPBA Research Committee, I would like to express my gratitude to the IHPBA Research Committee for awarding me the 2016-2017 Kenneth Warren Fellowship. This grant supports my study entitled “Therapeutic Use of Human Adipose-derived Stromal Cells in a Murine Model of Severe Acute Pancreatitis” under the mentorship of Drs.

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]